PCYS yields 20000000.00% · ABBV yields 3.06%● Live data
📍 PCYS pulled ahead of the other in Year 1
Combined, PCYS + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of PCYS + ABBV for your $10,000?
PrimeCare Systems, Inc., together with its subsidiaries, engages in the creation, ownership, maintenance, and marketing of patient management systems primarily in the United States. The company offers PrimeCare Version Ten, a multitier patient management system; and CodeComplierJ, an application software program that organizes the data in the proper classification and also calculates the evaluation and management reimbursement code level for third party payers. Its principal target markets include national and local health care systems, military organizations, correctional facilities, health maintenance organizations, hospitals with outpatient services, ambulatory/outpatient medical facilities, clinics, group practices, and solo practitioners. The company also creates, owns, maintains, and markets Web sites containing secure Internet enhanced and targeted components of the PrimeCare System. Its Web sites include PrimeCareOnTheWeb.com, a physician and patient interactive Website; YourOwnDoctor.com, which provides free individual Websites for physicians, physician groups, and other health care providers who register for PrimeCareOnTheWeb; and YourOwnHealth.com, an online health and wellness Website. The company focuses on selling its products directly to at-risk healthcare entities, and through distributors and private labeling opportunities. PrimeCare Systems, Inc. was incorporated in 1994 and is based in Newport News, Virginia.
Full PCYS Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.